Skip to content
Search

Latest Stories

RPS England director Ravi Sharma resigns to take up top job at Luton & Dunstable University Hospital

The Royal Pharmaceutical Society (RPS) England director, Ravi Sharma, has resigned after four years on the job.

He will be leaving the RPS in October to join Luton and Dunstable University Hospital, part of the Bedfordshire Hospitals NHS Foundation Trust group, as head of pharmacy.


RPS will be commencing the recruitment of a new director for England shortly and in the interim Ravi will be working with Paul Bennett, the RPS CEO, to help in delivery of key objectives and in the appointment of his successor.

Paul commented: “Ravi has made a significant contribution to the organization during his time with us. His drive and enthusiasm for advancing the recognition of the role of the Society itself and of pharmacists and professional practice is probably best reflected by his desire to ensure a real focus on personalized medicines and his work on equality and diversity, workforce wellbeing, and most recently the development of a new vision for pharmacy in England.

"He has developed stronger relationships and collaborative working with Government, Department of Health and Social Care, NHS England, professional leadership bodies, organisations and patient groups over the years to support implementation of our policies and advocacy work.

“Ravi became a Fellow of the Society in 2022, in well-deserved recognition of his contribution to the profession and I know we can expect to see him remain close to the work of the RPS and a real advocate for the Society’s professional leadership role.

Ravi Sharma commented: "It’s been an honour and a privilege to lead the team in England at RPS on behalf of our members, and the wider profession.

“I want to pay tribute to the dedication of my colleagues who have been instrumental in supporting the profession through Covid-19, raising the profile of pharmacy with NHS leaders and politicians and bringing our strategy on inclusion and diversity to life.

“Our recent collaborative work on co-creating a vision for pharmacy in England will provide the profession with a blueprint for the future. This work will continue, I look forward to seeing it develop from my new vantage point within the NHS.

“Improving care for patients and the public through pharmacy remains my personal mission. I am hugely excited about the opportunity to work with the senior leadership team at Bedfordshire Hospitals NHS Foundation Trust. I am looking forward to putting theory into practice, working with the fantastic team who are delivering critical NHS hospital services.

“I’m very appreciative of the fantastic opportunities I’ve had at RPS and I am confident the organisation will continue to represent the best of pharmacy and professional leadership in the future.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less